explore -WSS

explore

author：focus 2025-09-03 11:59:34 - browse：2368

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Testing GLP

WSS

Biotech investment managers search for lucrative opportunities

Plastic surgeons increase patient psychiatric screenings

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Plastic surgeons increase patient psychiatric screenings

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Asbestos ban is immediate, but health effects will linger for decades

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Cancer drug shortages should be causing more outrage

Leading voice in opioid treatment defends methadone clinic system

In Memoriam: Notable people who died in 2023

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Activists slam private health insurers over coverage restrictions

With Wegovy coverage, Medicare patients may face high costs

Bright Health sells Medicare Advantage business to Molina

Creating egg and sperm cells from stem cells raises ethical issues

leisure time

Health AI adoption puts security, privacy startups on investors' radar

Creating egg and sperm cells from stem cells raises ethical issues

Adam's Take: Intra

This gene therapy has record $4.25 million price. It's saved children.

Health AI adoption puts security, privacy startups on investors' radar

Readout LOUD podcast, live from the STAT Breakthrough Summit East

knowledge

hotspot

entertainment

entertainment